Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome

Barletta, Maria Angela; Marino, G.; Spagnolo, Barbara; Bianchi, Francesco Paolo; Falappone, Paola Chiara Francesca; Spagnolo, Luca; Gatti, Pietro

doi:10.1007/s10238-022-00871-8

Cited by 19 publications

(13 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicates that Lipoic Acid could perturb the CD68.N gene set by affecting the DNA methylation levels of IL6 and IL10, two key markers in cytokine storms related to COVID-19. Lipoic Acid has also been proven to have beneficial effects on COVID-19 severity by inhibiting the overproduction of reactive oxygen species (ROS) and inflammatory cytokines [10, 11].…”

Section: Resultsmentioning

confidence: 99%

“…While this list of metabolites serves as potential biomarkers for the disease, it also highlights a group of modulators for regulating the severity of or treating COVID-19. Several top-ranked nutraceuticals, such as lipoic acid [10, 11], N-acetyl-D-glucosamine [21], calcitriol (vitamin D3) [22], vitamin A/tretinoin [23], and spermine [24], have been suggested to have beneficial effects when used in symptom management and treatment of COVID-19.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Utilizing Pre-trained Network Medicine Models for Generating Biomarkers, Targets, Re-purposing Drugs, and Personalized Therapeutic Regimes: COVID-19 Applications

Xiong¹

2023

Preprint

View full text Add to dashboard Cite

In this paper, we present a novel pre-trained network medicine model called Selective Remodeling of Protein Networks by Chemicals (SEMO). We divide the global human protein-protein interaction (PPI) network into smaller sub-networks, and quantify the potential effects of chemicals by statistically comparing their target and non-target gene sets. By combining 9607 PPI gene sets with 2658 chemicals, we created a pre-trained pool of SEMOs, which we then used to identify SEMOs related to Covid-19 severity using DNA methylation profiling data from two clinical cohorts. The nutraceutical-derived SEMO features provided an effective model for predicting Covid-19 severity, with an AUC score of 81% in the training data and 80% in the independent validation data. Our findings suggest that Vitamin D3, Lipoic Acid, Citrulline, and Niacin, along with their associated protein networks,particularly STAT1, MMP2, CD8A, and CXCL8 as hub nodes,could be used to effectively predict Covid-19 severity. Furthermore, the severity-associated SEMOs were found to be significantly correlated with CD4+ and monocyte cell proportions. These insights can be used to generate personalized nutraceutical regimes by ranking the relative severity risk associated with each SEMO. Thus, our pre-trained SEMO model can serve as a fundamental knowledge map when coupled with DNA methylation measurements, allowing us to simultaneously generate biomarkers, targets, re-purposing drugs, and nutraceutical interventions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Utilizing Pre-trained Network Medicine Models for Generating Biomarkers, Targets, Re-purposing Drugs, and Personalized Therapeutic Regimes: COVID-19 Applications

Xiong¹

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…It has complementary roles in damaged tissue associated with a strong antioxidant and anti-inflammatory effect. [39,40] The processes participating included reversing MTX-induced testicular damage, as marked with decreased iNOS and TNF-α immunoreactivity. In addition, ALA reversed MTXinduced inflammatory hints because it notably reduced the level of TNF-α, which is consistent with the earlier stated antioxidant/anti-inflammatory effects of ALA. [20] Other studies have also shown that ALA has anti-inflammatory effect by decreasing the level of TNF-α.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Alpha-Lipoic Acid against Methotrexate on Testicular Damage in Rats

Armağan

Bayram

CANDAN>³

et al. 2023

Journal of Contemporary Medicine

View full text Add to dashboard Cite

Aim: The toxic effects of methotrexate, a chemotherapeutic, on the testicles is an important side effect. Methotrexate impairs spermatogenesis and fertility and causes oligospermia. In this study, we aimed to minimize the testicular toxicity, those being the side effects of methotrexate, by using the probable protective effects of α-lipoic acid, a potent antioxidant. Materials and Methods: Twenty-eight male Sprague Dawley rats that we employed in this research were separated into three groups as control (0.09% PS) (n=8), methotrexate (20 mg/kg) (n= 10), and methotrexate (20 mg/kg) + α-lipoic acid (100 mg/kg) (n= 10). We performed a histochemical analysis on the testicular tissue of rats using hematoxylin-eosin and Masson’s trichrome. We performed an immunohistochemical analysis using inducible nitric oxide synthase (iNOS) and tumor necrosis factor-alpha (TNF-α) primer ab. Results: The histochemical evaluation revealed a significant decrease in the methotrexate-induced testicular toxicity in the α-lipoic acid-treated groups. On the other hand, TNF-α and iNOS immunostaining results were also observed to support these results. Conclusion: The treatment use of α-lipoic acid succeeded in protecting against methotrexate-induced testicular damage through an α-lipoic acid-mediated antioxidant and anti-inflammatory mechanisms. α-lipoic acid can be used in combination with methotrexate as a protector against side effects during anticancer therapy. In the present study, it was shown that α-lipoic acid can be used in combination with methotrexate as a protector against side effects during anticancer treatment.

show abstract

“…Since combinations of treatments might be beneficial, trials of a promising candidate therapeutic in combination with other compounds are needed. There are examples of small studies with such combinations that are indeed showing promise, including CoQ10 and Se [ 105 ] and CoQ10 and lipoic acid [ 106 ].…”

Section: Can the Focus On Long Covid Research Provide Benefit For Me/...mentioning

confidence: 99%

Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID

Tate

Walker

Peppercorn

et al. 2023

IJMS

View full text Add to dashboard Cite

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex condition arising in susceptible people, predominantly following viral infection, but also other stressful events. The susceptibility factors discussed here are both genetic and environmental although not well understood. While the dysfunctional physiology in ME/CFS is becoming clearer, understanding has been hampered by different combinations of symptoms in each affected person. A common core set of mainly neurological symptoms forms the modern clinical case definition, in the absence of an accessible molecular diagnostic test. This landscape has prompted interest in whether ME/CFS patients can be classified into a particular phenotype/subtype that might assist better management of their illness and suggest preferred therapeutic options. Currently, the same promising drugs, nutraceuticals, or behavioral therapies available can be beneficial, have no effect, or be detrimental to each individual patient. We have shown that individuals with the same disease profile exhibit unique molecular changes and physiological responses to stress, exercise and even vaccination. Key features of ME/CFS discussed here are the possible mechanisms determining the shift of an immune/inflammatory response from transient to chronic in ME/CFS, and how the brain and CNS manifests the neurological symptoms, likely with activation of its specific immune system and resulting neuroinflammation. The many cases of the post viral ME/CFS-like condition, Long COVID, following SARS-CoV-2 infection, and the intense research interest and investment in understanding this condition, provide exciting opportunities for the development of new therapeutics that will benefit ME/CFS patients.

show abstract

Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome

Cited by 19 publications

References 74 publications

Utilizing Pre-trained Network Medicine Models for Generating Biomarkers, Targets, Re-purposing Drugs, and Personalized Therapeutic Regimes: COVID-19 Applications

Utilizing Pre-trained Network Medicine Models for Generating Biomarkers, Targets, Re-purposing Drugs, and Personalized Therapeutic Regimes: COVID-19 Applications

The Effect of Alpha-Lipoic Acid against Methotrexate on Testicular Damage in Rats

Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID

Contact Info

Product

Resources

About